Table 1.
Clinicopathologic characteristics of the cohort
| Clinicopathologic characteristics |
n (%) n = 29 |
||
|---|---|---|---|
| Gender | Male | 14 (48.3%) | |
| Female | 15 (51.7%) | ||
| Age (years) (median, range) | 55 (24–76) | ||
| Smoking history | Smoker or with smoking history | 12 (41%) | |
| Non-smoker | 17 (59%) | ||
| Disease stage | Early-stage | IA | 0 |
| IB | 1 (3.4%) | ||
| IIA | 2 (6.9%) | ||
| IIB | 3 (10.3%) | ||
| IIIA | 7 (24.1%) | ||
| Advanced-stage | IIIB | 4 (13.8%) | |
| IIIC | 2 (7.4%) | ||
| IVA | 6 (20.7%) | ||
| IVB | 4 (13.8%) | ||
| Surgery | Yes | 10 (34.5%) | |
| No | 19 (65.5%) | ||
| Radiotherapy | Yes | 5 (17%) | |
| No | 24 (83%) | ||
| Local or systemic regimen received | Neoadjuvant + surgery + adjuvant chemotherapy | 4 (14%) | |
| Surgery + adjuvant chemotherapy | 5 (17%) | ||
| Chemotherapy alone | 13 (48%) | ||
| Chemotherapy + radiotherapy | 3 (10%) | ||
| Surgery alone | 1 (3%) | ||
| Radiotherapy alone | 1 (3%) | ||
| No local or systemic regimen received | 2 (7%) | ||
| Best response | Stable disease | 12 (44%) | |
| Partial response | 7 (26%) | ||
| Unknown | 8 (30%) | ||
| Survival status | Still alive | 29 (100%) | |
| Follow-up (months) (median, range) | 14.2 (0.2–41.4) | ||
| PD-L1 status | High expression (TPS ≥ 50%) | 4 (14%) | |
| Low expression (TPS 5–49%) | 16 (55%) | ||
| Negative | 9 (31%) | ||